Non-Hodgkin Lymphoma
News
Drug gains orphan designation for DLBCL
The US Food and Drug Administration (FDA) has granted orphan designation to selinexor (KPT-330) for the treatment of diffuse large B-cell lymphoma...
News
Agricultural chemicals and the risk of NHL
EPA/John Messina After reviewing nearly 30 years’ worth of data, investigators have compiled a list of agricultural chemicals that appear to...
Conference Coverage
Hormone therapy may decrease risk of NHL
SAN DIEGO—The use of hormone therapy may lower the risk of B-cell non-Hodgkin lymphoma (NHL) in menopausal women, according to a presentation at...
News
NHL among top 10 most common cancers in US
Credit: Rhoda Baer A new report shows the rate of invasive cancer among US men and women dropped slightly from 2009 to 2010, and the most common...
News
Electronics workers may have elevated risk of death from NHL
Researchers have found evidence suggesting that men who work in microelectronics and business machine facilities may have an increased risk of...
News
Idelalisib more effective in CLL, iNHL than MCL
Credit: FDA Results of a phase 1 study suggest the PI3K delta inhibitor idelalisib can produce durable responses in certain patients with relapsed...
Conference Coverage
RIT can improve transplant outcomes in NHL, CLL
Ryan Cassaday, MD, of the University of Washington in Seattle, noted that RIT-augmented NMAT can produce long-term remissions in patients with...
News
Neutropenia prophylaxis, incidence increase with age
Credit: Volker Brinkmann New research suggests that older non-Hodgkin lymphoma patients are more likely than their younger counterparts to...
Conference Coverage
Allo-SCT can be effective in advanced SS, MF
Allogeneic stem cell transplant (SCT) proved particularly effective in patients with Sézary syndrome (SS). It also conferred benefits to mycosis...
Conference Coverage
Consortium study falls short of expectations
The North American PTCL Consortium set out to find a treatment that could best CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and...
Conference Coverage
Regimen shows promise for ENKTL
The combination of pegaspargase, gemcitabine, and oxaliplatin (P-Gemox) elicited a high rate of response in this cohort of 60 Chinese patients. P...